How to Access MDMA-Assisted Therapy in Canada

In Canada, the only legal way to access MDMA-assisted therapy is a case-by-case authorization from Health Canada. You cannot apply yourself. A licensed physician or nurse practitioner submits a case-specific request on your behalf, usually for post-traumatic stress disorder (PTSD) that has not responded to standard treatments. This guide walks through that pathway step by step.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334, Head of Western Operations, ATMA CENA, on 2026-05-27.

Key takeaways

• A case-by-case Health Canada authorization is the only legal route. Health Canada has not approved MDMA-assisted therapy for any condition. A January 2022 regulatory change again allowed physicians and nurse practitioners to request restricted drugs such as MDMA for individual patients with serious conditions when other treatments have failed.
• You cannot apply directly. Your prescribing physician or nurse practitioner initiates and submits the request. Finding a willing prescriber is the hardest step for most people.
• PTSD is the main use. Canadian MDMA requests are overwhelmingly for PTSD, supported by the Phase 3 MAPP1 and MAPP2 trials [Mitchell 2021; Mitchell 2023].
• Approval is not guaranteed. Each request is reviewed case by case. Health Canada data obtained by PsyCan indicate a sharp decline in approvals through 2025 [PsyCan 2025].
• The delivery model uses two therapists across a small number of long sessions, with preparation before and integration after.
• US approval is delayed, but Canadian access is separate. The FDA declined the Lykos application in August 2024 and asked for more research. Canada's authorization pathway operates independently of that decision.
• ATMA CENA supports preparation and integration, not the medical request itself. The request is initiated by your prescribing physician or nurse practitioner.

If you are exploring this pathway and want to understand where preparation and integration support fits, you can book a free information call to talk through your situation with ATMA CENA's clinical team.

What is the legal pathway to MDMA-assisted therapy in Canada?

MDMA has no Notice of Compliance (NOC) in Canada and is not approved for any medical indication. Patient access is available solely through a case-by-case authorization from Health Canada, which permits licensed physicians and nurse practitioners to request MDMA for a single patient with a serious condition when other treatments have failed, are unsuitable, or are unavailable. Each request is evaluated on its own merits, and approval is not guaranteed [Health Canada 2022]. MDMA is a Schedule I drug under the Controlled Drugs and Substances Act (CDSA), which is more restrictive than psilocybin's Schedule III status, though the practical case-by-case route is the same for both. A January 5, 2022 regulatory change added MDMA and psilocybin to the restricted drugs a practitioner may request for an individual patient. There is no direct-to-patient application. The request must come from a licensed physician or nurse practitioner who takes medical responsibility for your care.

The January 2022 regulatory change

Before 2022, there was no clear route for MDMA-assisted therapy. The 2020 Section 56(1) exemptions that drew media attention applied to psilocybin for a small number of terminally ill Canadians, not to MDMA. The January 5, 2022 change reversed an earlier rule that had blocked restricted drugs from Health Canada's case-by-case authorization route, and it again allowed practitioners to request both psilocybin and MDMA for individual patients with serious or life-threatening conditions where conventional treatments have failed [Health Canada 2022].

Provincial regulators

Provincial colleges have not generally issued MDMA-specific policies. Prescribing MDMA outside this authorization pathway would be highly unusual and would likely draw college review. In Quebec, the practice of psychotherapy is a reserved act under Bill 21, which applies to the psychotherapy portion of any MDMA-assisted therapy program regardless of the medical request.

Who qualifies for MDMA-assisted therapy in Canada?

These authorizations are case-specific and overwhelmingly target PTSD. There is no fixed eligibility checklist published by Health Canada, but in practice a supportable PTSD request includes a confirmed DSM-5 PTSD diagnosis with documented severity, a clear record of treatments already tried without adequate benefit, and evidence of ongoing functional impairment in work, relationships, or daily life. The published evidence base for MDMA-assisted therapy in PTSD is among the strongest in psychedelic medicine, drawn from the Phase 3 MAPP1 and MAPP2 trials [Mitchell 2021; Mitchell 2023]. Because the request is reviewed case by case, the strength of the clinical documentation matters more than meeting a single criterion. Other proposed uses are uncommon. The realistic 2026 pathway is PTSD-focused.

PTSD documentation a prescriber typically gathers

• A DSM-5 PTSD diagnosis with documented severity
• A record of first-line treatments already tried, including:
  • Trauma-focused cognitive behavioural therapy (TF-CBT)
  • Prolonged exposure therapy (PE)
  • Eye movement desensitization and reprocessing (EMDR)
  • SSRIs or SNRIs at a therapeutic dose for at least six weeks
• Documentation of why those treatments failed, were unsuitable, or were unavailable
• Notes on functional impairment in work, relationships, and daily activities
• Consideration of co-occurring conditions such as depression, anxiety, or substance use (an active substance use disorder usually needs stabilization first)

Service-related PTSD

A meaningful share of Canadian MDMA requests are for service-related PTSD in veterans, first responders such as police, paramedics, and firefighters, and corrections officers. A Phase 2 randomized trial specifically enrolled this population and found that 75 mg and 125 mg MDMA doses reduced PTSD severity more than a 30 mg control dose [Mithoefer 2018].

Common screening exclusions

• A personal history of a psychotic disorder, including schizophrenia, schizoaffective disorder, or bipolar I
• Active mania or recent hypomania
• Uncontrolled cardiovascular disease, uncontrolled high blood pressure, recent heart attack, severe structural heart disease, or significant arrhythmia
• Pregnancy
• Severe liver impairment
• Concurrent use of MAOI medications (an absolute contraindication because of serotonin syndrome and hypertensive crisis risk)
• An active substance use disorder that requires stabilization first
• An inability to provide informed consent

Watch out: MDMA raises heart rate and blood pressure and acts on the serotonin system. Several common antidepressants and the MAOI class can interact dangerously with it. Never stop or change a psychiatric medication on your own. Any taper is planned and supervised by your prescribing physician as part of the medical assessment.

How does the request work, step by step?

The request is initiated by a physician or nurse practitioner, not by you. The practical 2026 journey usually follows seven steps. The first one is the bottleneck most people face: finding a prescriber willing to apply.

Step 1: Find a willing prescribing physician or nurse practitioner

This is the step that stops most people, because relatively few Canadian prescribers have experience with these requests. Useful places to start:

• TheraPsil maintains a directory of trained Canadian clinicians and offers free patient consultations; its primary focus is psilocybin, and MDMA support varies by clinician.
• MAPS Canada supports Canadian research, training, and advocacy for MDMA-assisted therapy (it is a separate organization from the US-based drug developer).
• Established psychedelic-medicine clinics in several provinces have experience with this pathway and may have prescribers on staff or in their networks.
• ATMA CENA's clinical team does not initiate the medical request, but can discuss the regulatory framework and help orient you to appropriate resources.

Step 2: Document the treatments you have already tried

Your prescriber documents which PTSD treatments you have tried, at what dose and for how long, and why each did not work, was unsuitable, or was unavailable. For PTSD this usually covers:

• Trauma-focused psychotherapy attempts (TF-CBT, PE, EMDR) with dates and details
• Medication trials (SSRIs and SNRIs at a therapeutic dose for at least six weeks each)
• Add-on strategies where relevant (for example, prazosin for nightmares)
• A clear explanation of why these were inadequate

Step 3: Submit the request to Health Canada

Your prescribing physician or nurse practitioner completes the request, identifies a drug source, sets out the clinical rationale with peer-reviewed evidence such as the MAPP1 and MAPP2 trials [Mitchell 2021; Mitchell 2023], and submits it to Health Canada through the appropriate channel. The prescriber, not the patient, owns this submission.

Step 4: Wait for a case-specific decision

Health Canada reviews each request on its own merits. The agency looks at the seriousness of the condition, the evidence that other treatments have failed or are unavailable, the supporting clinical evidence, the proposed drug source, and the prescriber's plan for safe supervision. Historically, decisions came within roughly one to four weeks, but timelines have lengthened. Approval is not guaranteed, and Health Canada data obtained by PsyCan indicate a sharp decline in approvals through 2025 [PsyCan 2025]. It is reasonable to plan for several weeks or longer in 2026, and to prepare for the possibility of a refusal.

Step 5: Source the authorized drug supply

Once a request is authorized, the prescriber arranges a supply of pharmaceutical-grade MDMA. The supply chain for MDMA is more constrained than for psilocybin, and there is no large-scale no-charge supply program comparable to what has existed for some psilocybin cases. Supply arrangements can change, so the specific pharmaceutical-grade MDMA source should be confirmed with the prescribing physician or clinic at the time of the request.

Step 6: Complete the supervised therapy program with two therapists

MDMA-assisted therapy is delivered under the prescriber's authorization using a structured model: preparation sessions, a small number of long dosing sessions, and integration sessions afterward. In the Phase 3 protocols, dosing sessions ran several hours and were supported by two therapists working together in the room, with the prescribing clinician retaining medical responsibility throughout [Mitchell 2021; Mitchell 2023]. The two-therapist model is a defining feature of how MDMA-assisted therapy is delivered and is reflected in the published trials.

Step 7: Report outcomes to Health Canada after treatment

After treatment, the prescriber submits the standard follow-up reporting to Health Canada, covering outcomes, any adverse events, and clinical observations. This reporting is part of the prescriber's responsibility, not yours.

Pro tip: Bring a written treatment history to your first appointment with a prescriber. Dates, medication names, doses, durations, and the reason each treatment stopped are exactly what the request needs. Having this ready can shorten the time between your first visit and a submitted request.

What is the realistic picture for MDMA approvals?

MDMA authorization volumes in Canada have been consistently smaller than psilocybin, and the trend through 2025 was downward. Reliable current totals are not published, so treat any figure you see as approximate and dated.

Measure	Realistic picture
MDMA authorizations, relative volume	Far fewer than psilocybin; small numbers overall
Recent direction (2025)	Sharp decline in combined psychedelic approvals reported [PsyCan 2025]
Current 2026 totals	Not publicly available

Health Canada authorizations for MDMA have consistently run well below those for psilocybin. In late 2025, PsyCan reported a sharp decline in combined psychedelic approvals, running at roughly half the prior-year rate [PsyCan 2025]. Current 2026 figures are not publicly available. A few reasons the MDMA numbers stay lower than psilocybin:

• Narrower scope. Psilocybin authorizations cover several conditions, while MDMA requests are essentially PTSD-only.
• Tighter drug supply. There is no large-scale no-charge MDMA supply program comparable to some psilocybin pathways.
• Regulatory uncertainty. The August 2024 FDA decision on the Lykos application added some clinician hesitancy.

The honest takeaway: the pathway is real and operational, but it is narrow, the volume is small, and approval is not guaranteed.

What does the FDA decision mean for Canadian access?

The US drug developer Lykos Therapeutics submitted an application to the FDA for MDMA-assisted therapy for PTSD, based on the MAPP1 and MAPP2 Phase 3 trials. On August 8, 2024, the FDA issued a Complete Response Letter declining to approve the application and requesting additional research. Reported concerns included blinding integrity (MDMA's distinctive effects make it hard to keep participants and therapists unaware of who received the drug), durability of the data, and allegations of misconduct at certain trial sites. Lykos has said it accepts the FDA's requirement for a new Phase 3 trial. As of the most recent verifiable information in early 2026, that new trial had been committed to but had not started, and any US approval would be years away. The key point for Canadian patients: Health Canada operates independently of the FDA, and the Canadian authorization pathway continues regardless of the US decision.

A few clarifications matter here:

• Canadian access continues. The FDA decision is US-specific and does not change how Health Canada handles individual requests.
• A future Canadian approval is uncertain. Health Canada reviews similar evidence but makes its own decisions. A formal Canadian Notice of Compliance for MDMA-assisted therapy would depend on a successful future submission supported by additional Phase 3 work, and there is no defined timeline.
• The trial evidence still stands. The MAPP1 and MAPP2 studies remain published, peer-reviewed Phase 3 trials [Mitchell 2021; Mitchell 2023]. The FDA decision concerned regulatory and trial-conduct standards rather than a reversal of the efficacy findings.

This reflects the most recent verifiable information available in early 2026. Regulatory developments after that date, in either Canada or the US, could change the picture, so confirm the current status with your prescriber.

How does ATMA CENA support patients on this pathway?

ATMA CENA's role on the MDMA pathway is the same as for psilocybin: support around the therapy, not the medical request itself. ATMA CENA's own corporate clinics provide ketamine-assisted therapy; for MDMA it offers preparation and integration support alongside a prescriber's authorization.

• ATMA CENA does not initiate the medical request. The request is submitted by your prescribing physician or nurse practitioner.
• ATMA CENA supports preparation and integration through a structured, three-phase psychedelic-assisted therapy model, including the more extensive preparation and integration that an MDMA protocol involves.
• Through the CoCare program, ATMA CENA can partner with your existing therapist, where that therapist has the appropriate training and a service agreement is in place, so that your established therapeutic relationship continues alongside the clinical support the treatment involves. This can be valuable for trauma-focused work, where an existing therapeutic alliance often runs deep.

The practical entry point is a short information call: a conversation about whether this pathway fits your situation, what documentation you would need to gather, which Canadian resources might be a match, and how preparation and integration support would work alongside a prescriber's request.

Exploring this pathway and want to understand how preparation and integration support fits? You can book a free information call with ATMA CENA's clinical team.

Frequently asked questions

Can I apply for MDMA-assisted therapy myself as a patient?

No. Requests are initiated by a licensed physician or nurse practitioner, not by patients. You need a willing prescriber who will take medical responsibility for the request and your care. Finding that prescriber is usually the first and hardest step.

How do I find a physician willing to apply?

Start with organizations and clinics that work in this space. TheraPsil maintains a clinician directory and offers free patient consultations, MAPS Canada supports Canadian MDMA-assisted therapy advocacy and training, and several established psychedelic-medicine clinics have experience with this pathway. ATMA CENA's information call can help orient you to appropriate resources, though ATMA CENA does not initiate the medical request itself.

What conditions are MDMA requests usually for?

Overwhelmingly PTSD. The published Phase 3 evidence supports MDMA-assisted therapy for PTSD [Mitchell 2021; Mitchell 2023], and Canadian requests reflect that. Requests for other uses are uncommon, and the realistic 2026 pathway is PTSD-focused.

How long does a decision take?

Historically, decisions came within roughly one to four weeks, but timelines have lengthened, and Health Canada data obtained by PsyCan indicate a sharp decline in approvals through 2025 [PsyCan 2025]. It is reasonable to plan for several weeks or longer in 2026 and to prepare for the possibility of a refusal.

Has Health Canada approved MDMA-assisted therapy?

No. As of 2026, MDMA has no Notice of Compliance and is not approved for any medical indication in Canada. A case-by-case authorization is the only legal therapeutic pathway [Health Canada 2022]. The August 2024 FDA decision on the Lykos application added uncertainty about any future formal Canadian approval, which has no defined timeline.

Where does the MDMA come from?

Once a request is authorized, the prescriber arranges pharmaceutical-grade MDMA. The supply chain is more constrained than for psilocybin. Confirm the specific drug source with your prescribing physician or clinic at the time of the request, since supply arrangements can change.

What happens if my request is refused?

Approval is not guaranteed. If a request is refused, options can include resubmitting with stronger documentation, working with a different prescriber, or considering other PTSD treatments. Ketamine therapy is generally more accessible in Canada and has its own published PTSD evidence; you can read more about ATMA CENA's psychedelic-assisted therapy approach. Discuss the realistic options with your prescriber.

Can a nurse practitioner submit the request?

Yes. The January 2022 change authorized both physicians and nurse practitioners to request restricted drugs, including MDMA and psilocybin, for individual patients [Health Canada 2022].

Does Veterans Affairs Canada cover MDMA-assisted therapy?

No. Veterans Affairs Canada does not currently reimburse MDMA-assisted therapy or any psychedelic-assisted psychotherapy. Veterans who access MDMA-assisted therapy through this pathway pay out of pocket or through other third-party coverage.

Why are two therapists involved in the dosing sessions?

The Phase 3 trials used a two-therapist model, with both clinicians present and supporting the patient through long dosing sessions [Mitchell 2021; Mitchell 2023]. This model is built around continuous support and safety during the session and is a defining feature of how MDMA-assisted therapy is delivered.

Could MDMA-assisted therapy be formally approved in Canada one day?

Possibly, but there is no defined timeline. A formal Canadian approval would depend on a successful future submission to Health Canada, supported by additional Phase 3 research that the developer has committed to but, as of early 2026, had not started. Until then, the case-by-case authorization remains the only legal pathway.

Compliance disclaimer

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through a case-by-case authorization from Health Canada. That authorization is granted individually and is not guaranteed. Psilocybin authorizations are primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA authorizations are primarily granted for adults with PTSD.

This article is educational and does not constitute medical advice or a clinical recommendation for any individual. Decisions about treatment, eligibility, and requests rest with a qualified prescribing physician or nurse practitioner.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Health Canada (2022). Notice: Requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
2. Government of Canada. MDMA (Ecstasy). https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/mdma.html
3. Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6), 1025–1033. PMID: 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
4. Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10), 2473–2480. PMID: 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
5. Mithoefer, M.C. et al. (2018). MDMA-assisted psychotherapy for treatment of PTSD: a randomised, double-blind, dose-response phase 2 clinical trial. The Lancet Psychiatry. PMID: 29728331. https://pubmed.ncbi.nlm.nih.gov/29728331/
6. TheraPsil. https://therapsil.ca/
7. MAPS Canada. https://www.mapscanada.org/
8. PsyCan / Psychedelics Canada (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
9. Veterans Affairs Canada. Mental health benefits. https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
10. Psychiatric Times (2024). FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD. https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd
11. ATMA CENA. CoCare. https://atmacena.com/cocare/

Related articles in this cluster

• MDMA-Assisted Therapy in Canada (Hub)

---

Last updated: 2026-05-27. This article is reviewed every 3 months because it covers time-sensitive regulatory information.